Health Canada has authorized an adapted vaccine from Novavax to prevent COVID-19 in people age 12 and older. Novavax's product — Nuvaxovid XBB.1.5 Omicron subvariant COVID-19 vaccine — uses a ...

Novavax's vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September. People who have concerns or had a bad immunization ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Canada has detected its first presumptive case of H5 bird flu in a person, a teenager in the western province of British ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up. The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the ...

Novavax’s vaccine, reformulated to target the recently circulating JN.1 subvariant of Omicron, was authorized by Health Canada in September. People who have concerns or had a bad immunization ...